Project Grant F31CA290924
Award Date 12/1/25
Completion Date 5/12/28
Dollars Obligated $97K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This $156,136 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, aims to develop biochemical reagents and assays to analyze the structure and function of the PAX3-FOXO1 fusion protein that drives the rare disease alveolar rhabdomyosarcoma. Specifically, the project will generate recombinant PAX3-FOXO1 constructs and conduct preliminary structural screening using innovative nuclear magnetic resonance techniques. It will also establish in...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $481,052 to the Research Institute at Nationwide Children's Hospital to develop a preclinical/clinical pipeline to rapidly test new therapies for a deadly form of pediatric rhabdomyosarcoma (RMS) driven by mutant MYOD1. The primary goal is to identify effective treatments, including PI3K-targeted therapies, for this almost universally lethal malignancy by leveraging...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- This Project Grant award, valued at $611,591.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to research new strategies to overcome therapy resistance in Hedgehog pathway-driven medulloblastoma, the most common malignant pediatric brain cancer. The key focus areas of this research project include: 1) investigating a new...
- This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $151,040 in funding to St. Jude Children's Research Hospital Inc. to elucidate the role of an essential transcription factor in SWI/SNF-mutant rhabdoid tumors. The research aims to characterize the function of this poorly understood transcription factor and its interaction with a repressive chromatin-regulatory complex in the unique cellular environment resulting from the loss of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Houston System to investigate the role of the TAK1 signaling protein in the development and growth of rhabdomyosarcoma, a type of cancerous sarcoma. The $658,223 award, running from February 1, 2025 to January 31, 2030, will fund studies to examine the molecular mechanisms by which TAK1 drives rhabdomyosarcoma tumorigenesis and inhibits myogenic...
- This Project Grant award of $143,788 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research on genetic dependencies in pediatric low-grade gliomas (PLGG) with KIAA1549-BRAF rearrangements. The primary goals are to understand how the KIAA1549:BRAF fusion is activated, and why the POMT complex is essential for the survival of KIAA1549:BRAF-dependent cells. The research will test hypotheses related to the role of POMT enzymatic activity,...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $167,584.00 to the University of California, San Diego (UCSD) to generate human induced pluripotent stem cell (hiPSC) models of atypical teratoid rhabdoid tumors (ATRTs) - an aggressive form of pediatric brain cancer. The primary goals are to investigate the cell of origin for ATRTs and identify potential therapeutic vulnerabilities. Specifically, the award supports research to derive...